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Abstract
Inositol hexaphosphate (IP6), a naturally polyphosphorylated carbohydrate, has been reported to
have significant anticancer activity against numerous tumors, such as colon, prostate, breast, liver and
rhabdomyosarcomas. Recently, we established a new IP6-containing solution, designated as T-IP6,
produced by Taimatsu fermented rice germ. In this study, we examined the inhibitory effects of
tumor-associated antigens secreted from a gastric cancer cell line (MKN-45) and a hepatocellular
carcinoma cell l ine (HepG2) exposed to T-IP6. The tumor-associated antigens, such as
carcinoembryonic antigen (CEA) and protein induced by vitamin K absence or antagonists-II (PIVKA-
II), secreted from these cancer cell lines cultured with T-IP6 were significantly inhibited (P＜0.01),
compared with those in control cells (cultured without T-IP6) at 72 hrs, and this inhibition was
accompanied by morphological changes, respectively. In addition, T-IP6 inhibited CEA and PIVKA-II in
a dose-dependent manner.  These findings suggest that T-IP6 has an immunoinhibitory and
normalization effect in human cancer cells. 
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Introduction
Inositol hexaphosphate (IP6) is a polyphosphorylated
carbohydrate that is ubiquitous in plants such as grains
and legumes. IP6 is also found in most mammalian cells
and is particularly ubiquitous in cell membranes, where
it is found in conjugation with lipids as a
phosphatidylinositol and plays a biologically significant
role in intracellular signal transduction systems involved
in cellular proliferation and differentiation. 1-3) 
IP6 serves as a natural antioxidant and possibly as a
neurotransmitter. In fact, the phosphate groupings at
positions 1, 2, and 3 (axial-equatorial-axial) are unique
for IP6, providing a specific interaction with iron that
completely inhibits its ability to catalyze hydroxyl
radical formation.4) The antioxidant action of IP6 is
widely recognized and accepted. 
On the other hand, a novel anticancer action of IP6 has
also been shown using both in vivo and in vitro
experiments against various tumors, such as colon,
prostate, breast, liver and rhabdomyosarcomas; this
anticancer action occurs primarily via the regulation and
suppression of cellular proliferation and cell growth.3, 5-10)
In addition, the inhibitory effects of vascular endothelial
growth factor (VEGF) by IP6 have also been
investigated.11) VEGF is secreted by numerous tumor cells
and promotes the proliferation of endothelial cells and the
remodeling of neo-vessels. The induction of tumor
vascularization is mediated by the release of the
angiogenic factor VEGF. Thus, the inhibition of VEGF is
thought to be the most specific means of confirming the
anticancer action of IP6. However, the potential action of
IP6 on the inhibition of tumor-associated antigens (tumor
cell markers), such as carcinoembryonic antigen (CEA) 12)
and protein induced by vitamin K absence or antagonists-
II (PIVKA-II),13) secreted by gastric cancer cells and
hepatocellular carcinoma cells is poorly understood. 
Recently, we succeeded in establishing a new solution,
designated as T-IP6, containing IP6 produced by Taimatsu
fermented rice germ; this solution is commercially
available as a health food supplement.14) In the present
study, to confirm the ability of T-IP6 to act as an
anticancer agent, we investigated the inhibitory effects
of T-IP6 against CEA and PIVKA-II secreted from
cancer cell lines using a gastric cancer cell line, MKN-45
and a hepatocellular carcinoma cell line, HepG2. 
Materials and Methods 
Reagents
The Taimatsu fermented rice germ solution containing
IP6 (approximately 8.0 mg/mL), designated as T-IP6,
was prepared by Taimatsu Foods Co. (Niigata, Japan)
using the latest biological culturing and preparative
techniques and is currently available commercially as a
health food supplement.14) A chemiluminescent enzyme
immunoassay (CLEIA) kit for human carcinoembryonic
antigen (CEA) was purchased from Sysmex Co. (Hyogo,
Japan). An electro-chemiluminescence immunoassay
(ECLIA）kit for human protein induced by vitamin K
absence or antagonists-II (PIVKA-II) was purchased
from Eisai Co. (Tokyo, Japan).
Cell lines
The gastric cancer cell line (MKN-45) and hepatocellular
carcinoma cell line (HepG2) used in this study were
supplied by the Japanese Research Resource Bank (JRRB)
(Tokyo, Japan) and were cultured in RPMI 1640 medium
(GIBCO) and advanced-DMEM medium (GIBCO)
supplemented with 10 mM HEPES buffer, 2 mM glutamine,
and 10% fetal calf serum (FCS) (GIBCO) (subsequently
referred to as complete medium), respectively.
Preparation of MKN-45 and HepG2 cells cultured
with T-IP6
The MKN-45 and HepG2 cells (1x104) in the complete
medium described above were cultured in flasks
(Sumitomo Co., Tokyo, Japan) with or without T-IP6 at
various dilutions (1:100, 1:50, 1:25, or 1:10) at 37℃ for 72
hrs. Culture supernatants were used for the CEA and
PIVKA-II assays. Morphological changes in the cells
were observed using a phase-contrast microscope
(x100), and photographs were taken using a camera
body (Olympus Co., Tokyo, Japan) under the same
conditions.
Assays for the detection of CEA and PIVKA-II in
the culture supernatants
The detection of CEA and PIVKA-II in the culture
supernatants obtained from the MKN-45 and HepG2
cells cultured with or without T-IP6 at various dilutions
was performed using the CLEIA and ECLIA kits,
respectively. The experiments were performed in
triplicate and were repeated three times.
Statistical analysis
The mean and standard deviations (mean ± SD) were
calculated. The statistical analysis was performed using
the Student t-test or ANOVA (Dunnett test). Differences
were considered significant when the P value was less
than 0.05. 
Results and Discussion
Inositol hexaphosphate (IP6) is present in most
mammalian cell membranes, where it plays an important
role in regulating vital cellular functions, such as cellular
proliferation and differentiation, by participating in
intracellular signal transduction.1-3) In addition, IP6 has
been reported to have some anticancer activities against
numerous tumors, such as colon, prostate, breast, liver
and rhabdomyosarcomas.3, 5-10) 
Recently, we succeeded in establishing a new solution,
designated as T-IP6, containing IP6 produced by Taimatsu
fermented rice germ; this solution is commercially
available as a health food supplement,14) with the
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expectation that T-IP6 may have an anticancer action. In
this study, to confirm the anticancer action of T-IP6, we
investigated the inhibitory effects of T-IP6 against
tumor-associated antigens (CEA and PIVKA-II) secreted
from two types of cancer cell lines, MKN-45 (a gastric
cancer cell line) and HepG2 (a hepatocellular carcinoma
cell line). CEA is a biomarker that is present at high
levels in serum from individuals with colorectal
carcinoma, gastric carcinoma, pancreatic carcinoma, lung
carcinoma and breast carcinoma, but not in normal
healthy adult individuals.12) Meanwhile, PIVKA-II is an
abnormal prothrombin identified in individuals with
hepatocellular carcinoma (HCC) but not in normal
healthy individuals that has been suggested to be a
prognostic biomarker for rapid tumor progression.13) 
First, the inhibitions of CEA and PIVKA-II secreted
from MKN-45 and HepG2 cells by T-IP6 (1:10) were
analyzed using CLEIA and ECLIA systems, respectively.
As shown in Fig. 1, the CEA secreted from MKN-45 cells
cultured with T-IP6 was significantly inhibited (44.4
ng/mL, on average) (P＜0.01) at 72 hrs, compared with
that in control cells (120.3 ng/mL, on average) cultured
without T-IP6. On the other hand, the PIVKA-II secreted
from HepG2 cells cultured with T-IP6 was also
significantly inhibited (123.9 mAU/mL, on average)
(P＜0.01) at 72 hrs, compared with control cells (449.7
mAU/mL, on average) cultured without T-IP6 (Fig. 2).
These findings suggest that T-IP6 induced the
differentiation of these cell lines from malignant
phenotypes to normal phenotypes under the cell
reversion system. Furthermore, these data strongly
suggest that the T-IP6 action is involved in cell cycle
regulatory genes, differentiation genes, and oncogenes
mediated by various intracellular signal transduction
pathways. In particular, tumor suppressor genes, such as
p53, may be associated with the anticancer action of T-
IP6. In fact, it has been reported that the inhibition of
proliferation and growth in the human colon carcinoma
cell l ine (HT-29) by IP6 is influenced by tumor
suppressor genes (p53 and p21WAF1/CIP1).15) With this
point in mind, we suggested that T-IP6 also up-regulates
the expressions of the p53 and p21WAF1/CIP1 genes,
and their regulation by T-IP6 may induce the inhibition
of CEA and PIVKA-II secreted from MKN-45 and HepG2
cells. Since the loss of p53 function enhances the
resistance of cancer cells to chemotherapeutic agents,
the T-IP6-induced stimulation of the p53 gene may serve
as an attractive adjuvant for several chemotherapeutic
agents. 
In this study, the inhibition of CEA and PIVKA-II by
T-IP6 in MNK-45 and HepG2 cells was accompanied by
morphological changes (Fig. 3), suggesting that these
cells decreased during cell proliferation and growth.
Furthermore, these cells may have entered an apoptotic
phase as a result of the modulation of cell surface
antigen expression. For example, mucin marker (Gal-
GalNAc) expressed by precancer and cancer cells of the
colon, but not by normal cells, is reportedly modulated
by IP-6 treatment, resulting in the high levels of Gal-
GalNAc expression on these cells being decreased by
the regulation of mucin synthesis, resulting in
conversion to a normal cell phenotype.16) Thus, we are
vigorously investigating the reason for the T-IP6-
induced morphological changes in NKM-45 and HepG2
cells using several apoptotic analysis techniques as a
future step. 
Next, the inhibitions of CEA and PIVKA-II by T-IP6 at
various dilutions (1:100, 1:50. 1:25, or 1:10) in MKN-45
and HepG2 cells were also analyzed. Figures 4 and 5
showed that T-IP6 significantly inhibited (P＜0.05) CEA
and PIVKA-II secreted from these cancer cells. These
data clearly indicate that the inhibition of CEA and
PIVKA-II occurs in a dose-dependent manner.
The mechanisms involved in the inhibition of CEA
and PIVKA-II by T-IP6 are not fully understood at
present. However, the anticancer action of IP6 is based
on the hypotheses that exogenously administered IP6
may be internalized, dephosphorylated to IP1-5, and that
IP3 in particular may affect the anticancer action. In fact,
IP3 is known to have important roles in cellular signal
transduction, the regulation of cell function, and cell
proliferation/differentiation in various cells.17, 18) For
example, when the concentration of IP3 in cancer cells is
low, these cells grow vigorously without exhibiting
regular cell growth cycle. In contrast, when the
concentration of IP3 in cancer cells is high, these cells
stop growing. Thus, these findings indicate that IP3
plays critical roles in cell proliferation/growth. 
Two possible reasons can be considered explaining
the T-IP6-induced inhibition of the secretion of CEA and
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PIVKA-II from MKN-45 and HepG2 cells. First, the
exogenous administration of T-IP6 to MKN-45 and
HepG2 cells may result in its internalization and
dephosphorylation to IP3, increasing the concentration
of IP3 within the cells and effectively suppressing cell
proliferation, thereby markedly inhibiting CEA and
PIVKA-II secretion. Second, phospholipase C (PLC)
within the cells may be activated by the administration
of T-IP6, resulting in the dephosphorylation of
phosphatidylinositol binding IP6 to IP3 and increasing
the concentration of IP3 within the cells, thereby
markedly inhibiting CEA and PIVKA-II secretion. In fact,
a novel mechanism of IP6 against anticancer has been
reported to depend on the activation of PLC.19) However,
the detailed inhibitory mechanisms of CEA and PIVKA-II
by T-IP6 are not fully understood at the present time.
Thus, we are now vigorously investigating how to
analyze these mechanisms in our laboratories.
In conclusion, Taimatsu fermented rice germ solution
containing IP6 (T-IP6) significantly inhibited the
secretion of CEA and PIVKA-II from MKN-45 and
HepG2 cells. These findings provide the firs evidence
and also strongly indicate that T-IP6 has highly critical
properties in anticancer actions. Further analyses are
needed to demonstrate the detailed mechanisms of these
findings at the cellular and molecular levels.
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Figure 1. T-IP6-induced inhibition of CEA secreted from MKN-45 cells. MKN-45 cells were cultured with or without T-IP6
(1:10) for 72 hrs. The CEA in the culture supernatants was assayed using a CLEIA kit (see Materials and Methods section for
details). The experiment was performed in triplicate and was repeated three times. The statistical analysis was performed
using the Student t-test. *P＜0.01, none vs. T-IP6. 
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Figure 2. T-IP6-induced inhibition of PIVKA-II secreted from HepG2 cells. HepG2 cells were cultured with or without T-IP6
(1:10) for 72 hrs. The PIVKA-II in the culture supernatants was assayed using an ECLIA kit (see Materials and Methods
section for details). The experiment was performed in triplicate and was repeated three times. The statistical analysis was
performed using the Student t-test. *P＜0.01, none vs. T-IP6. 
Figure 3. T-IP6-induced morphological changes in MKN-45 and HepG2 cells. MKN-45 and HepG2 cells were cultured with or
without T-IP6 (1:10) for 72 hrs (see Materials and Methods section for details). The morphological changes were observed
using phase-contrast microscopy (x100). Photographs were taken with an Olympus camera body under the same conditions.
A and C: cultured without T-IP6. B and D: cultured with T-IP6.
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Figure 4. Dose-dependent inhibition of CEA secreted from MKN-45 cells cultured with T-IP6. MKN-45 cells were cultured
with or without T-IP6 at various dilutions (1:00, 1:50, 1:25, or 1:10) for 72 hrs. The CEA in the culture supernatants was
assayed using a CLEIA kit (see Materials and Methods section for details). The experiment was performed in triplicate and
was repeated three times. The statistical analysis was performed using an ANOVA (Dunnett test). *P＜0.05, none vs. T-IP6
(1:100, 1:50, 1:25, or 1:10, respectively). 
Figure 5. Dose-dependent inhibition of PIVKA-II secreted from HepG2 cells cultured with T-IP6. HepG2 cells were cultured
with or without T-IP6 at various dilutions (1:00, 1:50, 1:25, or 1:10) for 72 hrs. The PIVKA-II in the culture supernatants was
assayed using an ECLIA kit (see Materials and Methods section for details). The experiment was performed in triplicate and
was repeated three times. The statistical analysis was performed using an ANOVA (Dunnett test). *P＜0.05, none vs. T-IP6
(1:100, 1:50, 1:25, or 1:10, respectively). 
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要旨
本研究では、我々が開発したIP6含有たいまつ米胚芽発酵液（T-IP6）の癌細胞株(MKN-45および
HepG2)から分泌される腫瘍関連抗原（CEAまたはPIVKA-II）に対する影響を化学発光および電気
化学発光酵素免疫測定法で解析した。その結果、T-IP6で培養したMKN-45およびHepG2細胞から分
泌されるCEAまたはPIVKA-IIは、細胞の形態変化を伴いながら有意に抑制された（P＜0.01）。また、
T-IP6によるCEAまたはPIVKA-IIの抑制作用は濃度依存性であった（P＜0.05）。以上の結果から、
T-IP6にはヒトの癌細胞を正常化させる作用があることがわかった。
キーワード：CEA HepG2細胞　MKN-45細胞　PIVKA-II T-IP6 
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